Olga Tronina, Michał Brzdęk, Dorota Zarębska-Michaluk, Beata Lorenc, Justyna Janocha-Litwin, Hanna Berak, Marek Sitko, Dorota Dybowska, Włodzimierz Mazur, Magdalena Tudrujek-Zdunek, Ewa Janczewska, Jakub Klapaczyński, Witold Dobracki, Anna Parfieniuk-Kowerda, Rafał Krygier, Łukasz Socha, Robert Flisiak
AIM OF THE STUDY: The aim is to summarize the effectiveness and safety of genotype-specific and pangenotypic hepatitis C virus (HCV) treatments in patients with renal failure. MATERIAL AND METHODS: In the EpiTer-2 database, which includes data from 22 hepatology centers in Poland, 593 patients with HCV infection and kidney failure were identified. According to KDIGO 2022, they fulfilled the criteria of chronic kidney disease. Patients were divided into two groups: treated with genotype-specific regimens ( n = 428) and pangenotypic options ( n = 165), in relation to the stage of kidney disease determined using the glomerular filtration rate (GFR) (Cockcroft and Gault equation)...
December 2023: Clinical and Experimental Hepatology